Epithelial Ovarian Carcinoma Clinical Trial
Official title:
A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).
Status | Terminated |
Enrollment | 22 |
Est. completion date | August 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Females 18 years or older - Histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (serous, endometrioid or mucinous), who have undergone initial surgery or interval debulking surgery but have not reached complete remission of more than 6 months after first line platinum based chemotherapy, for one of the following reasons - Patients are platinum-refractory (no response) - Complete remission was not reached (partial responders) - Relapse within =6 months of remission (Platinum-resistant) - Platinum-based chemotherapy failure should have been confirmed by computerized tomography (CT)/magnetic resonance imaging (MRI) scan (Platinum-resistant) or by finding described as 'did not reach complete clinical remission' (Platinum-refractory or Platinum-partial response) Patients must have at least one measureable target lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria - Eastern Cooperative Oncology Group (ECOG) Performance status 0-2 Exclusion Criteria: - FIGO I,II epithelial ovarian cancer - FIGO III, IV clear cells epithelial ovarian cancer - Non-epithelial ovarian cancer - Borderline tumors (tumors of low malignant potential) - Prior or current systemic anti-cancer therapy for ovarian cancer [for example chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, vascular endothelial growth factor (VEGF) therapy or hormonal therapy] except first line Platinum-based chemotherapy (with or without bevacizumab) - Previous radiotherapy to the abdomen and pelvis - Malignancy other than epithelial ovarian cancer, except those that have been in clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the cervix or non-melanoma skin carcinomas - Clinically significant cardiovascular disease - Active autoimmune disease requiring treatment - History of severe forms of primary immune deficiencies - Systemic immunosuppressive therapy for any reason |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sotio a.s. |
Czech Republic, Germany, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (all cause mortality) | 72 weeks | Yes | |
Secondary | Progression Free Survival | Per modified RECIST | 72 weeks | No |
Secondary | Objective Response Rate | Per RECIST | 0, 8, 16, ,24, 32, 40, 48, 56, 64, 72 weeks | No |
Secondary | Biological Progression Free Interval | 0, 8, 16, 24, 32, 40, 48, 56, 64, 72 weeks | No | |
Secondary | Immunological Response | 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 weeks | No | |
Secondary | Frequency of Adverse Events | 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks | Yes | |
Secondary | Evaluation of Quality of Life via Functional Assessment of Cancer Therapy-Ovarian | 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT00349505 -
Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
|
Phase 2 | |
Recruiting |
NCT05470920 -
Genetic Testing Decision Aid
|
N/A | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01138137 -
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT02437812 -
Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
|
Phase 2 | |
Recruiting |
NCT02344095 -
A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT05086692 -
A Beta-only IL-2 ImmunoTherapY Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT04834544 -
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
|
Phase 2 |